Skip to main content
. 2020 Jun 17;11:1256. doi: 10.3389/fimmu.2020.01256

Figure 2.

Figure 2

Therapeutic responses to DNPs depend on the PD-1/PD-L pathway. (A–E) EAE was induced in B6 (WT), PD-1-KO (B,C), PD-L1-KO (D), and PD-L2-KO (E) mice, and disease onset and progression was monitored and scored. At EAE onset (day 11) mice were treated with DNPs every other day until day 21 and control mice were treated with vehicle (Vh; glucose 5%). Data were analyzed by two-way ANOVA (NS, not significant; *p < 0.05; ***p < 0.001, #p < 0.0001) and are representative of 2 experiments with n = 6–18. (F) B6 (WT), PD-1-KO, PD-L1-KO, PD-L2-KO and PD-L1+L2-KO mice were treated with DNPs or Vh (glucose 5%). Twenty-four hours later spleens were harvested and IDO activity in homogenized tissues was measured by assessing Kyn production ex vivo. Kyn levels were significantly higher (p < 0.0001, n = 4–9, Student's t-test) in spleens from all mice treated with DNPs regardless of their genotype, relative to Kyn levels in spleens from vehicle-treated WT mice.